Broad Effectiveness: Study With Aripiprazole
Phase 3
Completed
- Conditions
- Schizoaffective DisorderSchizophrenia
- Registration Number
- NCT00036361
- Brief Summary
The purpose of this study is to learn if aripiprazole is effective in the treatment of a large number of persons diagnosed with schizophrenia or schizoaffective disorders
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 444
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Safety Assessments
- Secondary Outcome Measures
Name Time Method Safety Assessments
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of aripiprazole in treating schizophrenia and schizoaffective disorder?
How does aripiprazole compare to standard antipsychotics in phase 3 trials for schizophrenia?
What biomarkers correlate with aripiprazole response in patients with schizoaffective disorder?
What adverse events are associated with aripiprazole in large-scale schizophrenia trials?
Are there combination therapies involving aripiprazole for treatment-resistant schizophrenia?
Trial Locations
- Locations (1)
Local Institution
🇺🇸Wallingford, Connecticut, United States
Local Institution🇺🇸Wallingford, Connecticut, United States